DNA fusion gene vaccines

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 1, 2010, Pages 47-54

  Holst, Peter Johannes ^a   Bassi, Maria Bassi ^a   Thomsen, Allan Randrup ^a   Christensen, Jan Pravsgaard ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antigen engineering; Antigen presentation; Cytokine; DNA vaccine; Immunogenicity; Viral vector

Indexed keywords

CHEMOKINE; CYTOKINE; DNA VACCINE; VIRUS VECTOR;

ANTIBODY RESPONSE; ANTIGEN PRESENTATION; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DNA IMMUNIZATION; DNA SEQUENCE; DRUG POTENCY; FUSION GENE; GENETIC IMMUNIZATION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PROTEIN SYNTHESIS; REVIEW;

ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; GENE FUSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; VACCINES, DNA;

EID: 76749163655     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Lu S, Wang S, Grimes-Serrano JM: Current progress of DNA vaccine studies in humans. Expert Rev Vaccines (2008) 7(2):175-191.
2. Kwissa M, Amara RR, Robinson HL, Moss B, Alkan S, Jabbar A, Villinger F, Pulendran B: Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med (2007) 204(11):2733-2746.
3. Chiarella P, Massi E, De Robertis M, Fazio VM, Signori E: Strategies for effective naked-DNA vaccination against infectious diseases. Rec Pat Anti-infect Drug Discov (2008) 3(2): 93-101.
4. Xu R, Megati S, Roopchand V, Luckay A, Masood A, Garcia-Hand D, Rosati M, Weiner DB, Felber BK, Pavlakis GN, Sidhu MK et al: Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine (2008) 26(37):4819-4829.
5. Calarota SA, Weiner DB: Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev (2004) 199:84-99.
6. Hung CF, Monie A, Alvarez RD, Wu TC: DNA vaccines for cervical cancer: From bench to bedside. Exp Mol Med (2007) 39(6):679-689.
7. Memarnejadian A, Roohvand F, Arashkia A, Rafati S, Shokrgozar MA: Polytope DNA vaccine development against hepatitis C virus: A streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Pept Lett (2009) 16(7):842-850.
8. Mok H, Lee S, Wright DW, Crowe JE Jr: Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope. Vaccine (2008) 26(37):4775-4782.
9. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, Schreiber RD et al: Batf3 deficiency reveals a critical role for CD8α+ dendritic cells in cytotoxic T cell immunity. Science (2008) 322(5904):1097-1100.
10. Boyle JS, Koniaras C, Lew AM: Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: Cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol (1997) 9(12):1897-1906.
11. Maecker HT, Umetsu DT, DeKruyff RH, Levy S: Cytotoxic T cell responses to DNA vaccination: Dependence on antigen presentation via class II MHC. J Immunol (1998) 161(12): 6532-6536.
12. Spellerberg MB, Zhu D, Thompsett A, King CA, Hamblin TJ, Stevenson FK: DNA vaccines against lymphoma: Promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J Immunol (1997) 159(4):1885-1892.
13. Ji H, Wang TL, Chen CH, Pai SI, Hung CF, Lin KY, Kurman RJ, Pardoll DM, Wu TC: Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther (1999) 10(17):2727-2740.
14. Kim MS, Sin JI: Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology (2005) 116(2):255-266.
15. Valentin A, Chikhlikar P, Patel V, Rosati M, Maciel M, Chang KH, Silvera P, Felber BK, Pavlakis GN, August JT, Marques ET: Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in rhesus macaques reveals antigenspecific T-cell responses with distinct phenotypes. Vaccine (2009) 27(35):4840-4849.
16. Bartholdy C, Stryhn A, Hansen NJ, Buus S, Thomsen AR: Incomplete effector/memory differentiation of antigenprimed CD8+ T cells in gene gun DNA-vaccinated mice. Eur J Immunol (2003) 33(7):1941-1948.
17. Lin CT, Chang TC, Chao A, Dzeng E, Soong YK, Hung CF, Lai CH: Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin. J Biomed Sci (2005) 12(2):279-287.
18. Rodriguez F, Zhang J, Whitton JL: DNA immunization: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol (1997) 71(11):8497-8503.
19. Uger RA, Barber BH: Creating CTL targets with epitope-linked β2-microglobulin constructs. J Immunol (1998) 160(4): 1598-1605.
20. Peng S, Trimble C, Ji H, He L, Tsai YC, Macaes B, Hung CF, Wu TC: Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. J Biomed Sci (2005) 12(5):689-700.
21. Perkins SD, Hartley MG, Lukaszewski RA, Phillpotts RJ, Stevenson FK, Bennett AM: VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. Vaccine (2005) 23(16):1931-1940.
22. Ackerman AL, Giodini A, Cresswell P: A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity (2006) 25(4): 607-617.
23. Freigang S, Eschli B, Harris N, Geuking M, Quirin K, Schrempf S, Zellweger R, Weber J, Hengartner H, Zinkernagel RM: A lymphocytic choriomeningitis virus glycoprotein variant that is retained in the endoplasmic reticulum efficiently cross-primes CD8+ T cell responses. Proc Natl Acad Sci USA (2007) 104(33):13426-13431.
24. Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PJ, Lin CT, Boyd DA, Wu TC: Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 11(12):1011-1018.
25. Kim D, Hoory T, Monie A, Ting JP, Hung CF, Wu TC: Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J Immunol (2008) 180(10):7019-7027.
26. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC: A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res (2009) 15(1):361-367.
27. Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB, Harper LB, Pauley CJ, Niu Z, Denisova L, Follmer TT et al: Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther (2004) 11(8):711-721.
28. Williams MA, Tyznik AJ, Bevan MJ: Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature (2006) 441(7095):890-893.
29. Schirmbeck R, Reimann J, Kochanek S, Kreppel F: The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther (2008) 16(9):1609-1616.
30. Prasad SA, Norbury CC, Chen W, Bennink JR, Yewdell JW: Cutting edge: Recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells. J Immunol (2001) 166(8):4809-4812.
31. Gomez CE, Najera JL, Krupa M, Esteban M: The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther (2008) 8(2):97-120.
32. Bartholdy C, Stryhn A, Christensen JP, Thomsen AR: Single-epitope DNA vaccination prevents exhaustion and facilitates a broad antiviral CD8+ T cell response during chronic viral infection. J Immunol (2004) 173(10):6284-6293.
33. Holst PJ, Bartholdy C, Stryhn A, Thomsen AR, Christensen JP: Rapid and sustained CD4+ T-cell independent immunity from adenovirus encoded vaccine antigens. J Gen Virol (2007) 88(Pt 6):1708-1716.
34. Richardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, Feldmann H, Kobinger GP: Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS ONE (2009) 4(4):e5308.
35. Holst PJ, Sorensen MR, Mandrup Jensen CM, Orskov C, Thomsen AR, Christensen JP: MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J Immunol (2008) 180(5):3339-3346.
36. Diebold SS, Cotten M, Koch N, Zenke M: MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther (2001) 8(6):487-493.
37. Grujic M, Holst PJ, Christensen JP, Thomsen AR: Fusion of a viral antigen to invariant chain leads to augmented T-cell immunity and improved protection in gene-gun DNA-vaccinated mice. J Gen Virol (2009) 90(Pt 2):414-422.
38. Lamb CA, Cresswell P: Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes. J Immunol (1992) 148(11):3478-3482.
39. Lasaro MO, Tatsis N, Hensley SE, Whitbeck JC, Lin SW, Rux JJ, Wherry EJ, Cohen GH, Eisenberg RJ, Ertl HC: Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat Med (2008) 14(2): 205-212.
40. Compaan DM, Gonzalez LC, Tom I, Loyet KM, Eaton D, Hymowitz SG: Attenuating lymphocyte activity: The crystal structure of the BTLA-HVEM complex. J Biol Chem (2005) 280(47):39553-39561.
41. Cheung TC, Steinberg MW, Oborne LM, Macauley MG, Fukuyama S, Sanjo H, D'Souza C, Norris PS, Pfeffer K, Murphy KM, Kronenberg M et al: Unconventional ligand activation of herpesvirus entry mediator signals cell survival. Proc Natl Acad Sci USA (2009) 106(15):6244-6249.
42. Chen M, Wang YH, Wang Y, Huang L, Sandoval H, Liu YJ, Wang J: Dendritic cell apoptosis in the maintenance of immune tolerance. Science (2006) 311(5764):1160-1164.
43. Lee JM, Mahtabifard A, Yamada R, Crystal RG, Korst RJ: Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor κB cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors. Clin Cancer Res (2002) 8(11):3561-3569.
44. Whitbeck JC, Muggeridge MI, Rux AH, Hou W, Krummenacher C, Lou H, van Geelan A, Eisenberg RJ, Cohen GH: The major neutralizing antigenic site on herpes simplex virus glycoprotein D overlaps a receptor-binding domain. J Virol (1999) 73(12):9879-9890.
45. Chentoufi AA, Zhang X, Lamberth K, Dasgupta G, Bettahi I, Nguyen A, Wu M, Zhu X, Mohebbi A, Buus S, Wechsler SL et al: HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J Immunol (2008) 180(1):426-437.
46. Guo JH, Fan MW, Sun JH, Jia R: Fusion of antigen to chemokine CCL20 or CXCL13 strategy to enhance DNA vaccine potency. Int Immunopharmacol (2009) 9(7-8):925-930.
47. Williman J, Young S, Buchan G, Slobbe L, Wilson M, Pang P, Austyn J, Preston S, Baird M: DNA fusion vaccines incorporating IL-23 or RANTES for use in immunization against influenza. Vaccine (2008) 26(40):5153-5158.
48. Tenbusch M, Kuate S, Tippler B, Gerlach N, Schimmer S, Dittmer U, Uberla K: Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity. BMC Immunol (2008) 9:13.
49. Fan H, Tong T, Chen H, Guo A: Immunization of DNA vaccine encoding C3d-VP1 fusion enhanced protective immune response against foot-and-mouth disease virus. Virus Genes (2007) 35(2):347-357.
50. Ferrone CR, Perales MA, Goldberg SM, Somberg CJ, Hirschhorn-Cymerman D, Gregor PD, Turk MJ, Ramirez-Montagut T, Gold JS, Houghton AN, Wolchok JD: Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res (2006) 12(18):5511-5519.
51. Chiarella P, Massi E, De Robertis M, Sibilio A, Parrella P, Fazio VM, Signori E: Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration. Expert Opin Biol Ther (2008) 8(11):1645-1657.
52. Seo SH, Jin HT, Park SH, Youn JI, Sung YC: Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine (2009) 27(42):5906-5912.
53. Barouch DH, McKay PF, Sumida SM, Santra S, Jackson SS, Gorgone DA, Lifton MA, Chakrabarti BK, Xu L, Nabel GJ, Letvin NL: Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol (2003) 77(16):8729-8735.
54. Masopust D, Ha SJ, Vezys V, Ahmed R: Stimulation history dictates memory CD8 T cell phenotype: Implications for prime-boost vaccination. J Immunol (2006) 177(2):831-839.
55. Cox KS, Clair JH, Prokop MT, Sykes KJ, Dubey SA, Shiver JW, Robertson MN, Casimiro DR: DNA Gag/adenovirus type 5 (Ad5) Gag and Ad5 Gag/Ad5 Gag vaccines induce distinct T-cell response profiles. J Virol (2008) 82(16):8161-8171.
56. Hsieh CJ, Kim TW, Hung CF, Juang J, Moniz M, Boyd DA, He L, Chen PJ, Chen CH, Wu TC: Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine (2004) 22(29-30):3993-4001. (Pubitemid 39208763)